Eluxadoline Dosing for IBS-D
The standard recommended dose of eluxadoline for IBS-D is 100 mg twice daily with food 1, 2.
Standard Dosing
- 100 mg twice daily with food is the FDA-approved standard dose for most adults with IBS-D 1, 2
- Must be taken with food at both doses 2
- If a dose is missed, take the next dose at the regular time—never double up 2
Reduced Dosing: 75 mg Twice Daily
Use the lower 75 mg dose twice daily with food in the following specific situations 1, 2:
- Intolerance to 100 mg dose (most commonly due to constipation, nausea, or abdominal pain) 1, 2
- Hepatic impairment: Mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, as drug exposure increases 6-fold and 4-fold respectively 1, 2
- Renal impairment: Moderate or severe renal impairment (eGFR <60 mL/min/1.73 m²) or end-stage renal disease not yet on dialysis (eGFR <15 mL/min/1.73 m²) 2
- Drug interactions: Concurrent use of OATP1B1 inhibitors (which increase eluxadoline exposure) 1, 2
- Elderly patients (≥65 years): Consider starting with 75 mg, as this subgroup showed greater response rates at the lower dose compared to 100 mg, with a slightly higher adverse event rate overall 3
Critical Safety Considerations
Absolute Contraindications - DO NOT PRESCRIBE 1, 2:
- Patients without a gallbladder (highest risk for pancreatitis and sphincter of Oddi spasm—fatal cases reported) 1, 2, 4
- Alcohol use: >3 alcoholic beverages per day, or any history of alcoholism, alcohol abuse, or alcohol addiction 1, 2
- Pancreatitis history or structural pancreatic disease, including pancreatic duct obstruction 2
- Biliary disease: Known/suspected biliary duct obstruction or sphincter of Oddi disease/dysfunction 2
- Severe hepatic impairment (Child-Pugh Class C)—drug levels increase 16-fold 2
- Constipation history: Chronic or severe constipation, sequelae from constipation, or mechanical GI obstruction 2
Common Pitfalls to Avoid:
The most serious adverse events (pancreatitis and sphincter of Oddi spasm) occurred predominantly in patients without a gallbladder, with 8 of 10 sphincter of Oddi events occurring within the first week of therapy at the 100 mg dose 4. All cases resolved with drug discontinuation, but this underscores the absolute contraindication in post-cholecystectomy patients.
Discontinue eluxadoline immediately if 2:
- Severe constipation develops
- New or worsening abdominal pain occurs (especially with nausea/vomiting)
- Acute biliary-type pain with elevated liver or pancreatic enzymes develops
Efficacy Data
The 100 mg twice daily dose demonstrated sustained efficacy over 26 weeks, with 27-30% of patients achieving the FDA composite endpoint (simultaneous improvement in abdominal pain and stool consistency for ≥50% of treatment days) compared to 16-17% with placebo 1, 5. The drug particularly improves stool consistency and urgency, with somewhat less robust effects on abdominal pain 1.
Most common adverse events at therapeutic doses are constipation (8%), nausea (7%), and abdominal pain (7%), with discontinuation rates of approximately 8% 1, 5.